



an Open Access Journal by MDPI

## Metal-Based Complexes in Cancer Treatment

Guest Editors:

**Dr. Tania Gamberi**

Department of Experimental and  
Clinical Biomedical Sciences,  
University of Florence, Florence,  
Italy

**Dr. Muhammad Hanif**

School of Chemical Sciences,  
University of Auckland, Private  
Bag 92019, Auckland 1142, New  
Zealand

Deadline for manuscript  
submissions:

**closed (31 March 2022)**

### Message from the Guest Editors

Dear Colleagues,

Metal-based complexes contribute a vital part in the available arsenal of cytotoxic agents today. Platinum(II) complexes, specifically targeting genomic DNA (e.g., cisplatin and carboplatin), are widely used in the clinic for the treatment of various cancers. This Special Issue will include original research and review articles on the use of platinum and nonplatinum metal complexes in cancer therapy. In particular, papers focusing on the design and developing targeted metal-based anticancer agents, understanding their mechanisms of action, and innovative drug delivery approaches will be considered. Topics of interest for this Special Issue include but are not limited to the following:

- medicinal chemistry of metal-based anticancer drugs;
- synthesis/improvement of platinum and nonplatinum metal complexes;
- mechanisms of action/biological targets of metal-based drugs;
- clinical applications of metal-based anticancer agents;
- uptake, toxicity, and resistance of metal-based anticancer agents;
- metal-based complexes in targeted drug delivery;
- metal-based drugs in cancer combinatorial therapy.



[mdpi.com/si/44679](https://mdpi.com/si/44679)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)